

NUROSENE ANNOUNCES ADVISORY ROLE WITH RARE-X

TORONTO, ON, January 18, 2023 – Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF) a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry through its wholly owned subsidiary NetraMark, is pleased to announce an advisory relationship with RARE-X, the Global Genes collaborative platform for rare disease patients to share their data to accelerate the development of diagnoses and treatments.

“I am pleased to announce that NetraMark has agreed to an advisory role with RARE-X. As part of the relationship, Dr. Joseph Geraci will join RARE-X's Advisory Board for Xcelerate RARE: An Open Science Data Challenge and RARE-X will provide NetraMark access to their world class rare disease data sets.” – President of NetraMark, Josh Spiegel.

Core to this advisory role is the RARE-X Open Science Data Challenge which brings together industry leaders, such as the RTW Charitable Foundation, Roche, the Alliance for Artificial Intelligence in Healthcare and includes expert advice from the U.S. Food and Drug Administration, as sited at <https://rare-x.org/open-science-data-challenge/>. The Open Science Challenge presents a unique opportunity for NetraMark to further validate its proprietary NetraAI technology, its capabilities to find unique insights from small datasets and the opportunity to connect with pharmaceutical companies working towards cures for rare diseases.

“We are excited to partner with RARE-X and contribute to their mission of accelerating the search for cures for rare diseases,” said Dr. Joseph Geraci. “Our NetraAI technology has a proven track record of finding valuable insights in small datasets, and we believe it will be a valuable asset to RARE-X's efforts to bring hope to patients with rare diseases.”

“We are thrilled that Netramark is partnering with us in this Open Science Data Challenge,” said Karmen Trzupsek, Senior Director of Scientific Programs for Global Genes. “Together, our goal is to leverage Netramark's technology and apply it to patient-owned data on the RARE-X platform to accelerate the generation of therapeutic hypotheses for rare neurodevelopmental disorders and to advance research to benefit rare disease patients.”

About Nurosene

Nurosene is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry, through its wholly owned subsidiary NetraMark.

For further details on the Company please see the most recent investor update presentation, found on the Company's Investor page at: <https://nurosene.com/investors>

About RARE-X

RARE-X is a program of Global Genes focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Enabled by best-in-class technology, patients, researchers, and other technology

vendors, RARE-X gathers structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data-sharing technology. Through RARE-X, Global Genes is building the largest collaborative patient-driven, open-data access project for rare diseases globally.

For more information, visit www.rare-x.org.

Company contact information:

Swapam Kakumanu - CFO | swapam@nurosene.com | 403-681-2549

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding our strategic focus going forward, the validation of the NetraAI technology, its capabilities to find unique insights from small datasets and the value it might bring to RARE-X's efforts to advance research to benefit rare disease patients and the opportunity to connect with pharmaceutical companies working towards cures for rare diseases, which are based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown, risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management's Discussion and Analysis for the year ended September 30, 2021 along with the risk factors set out in the corporate presentation. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.